ORGO - Organogenesis Holdings Inc.
After hours:
| Previous close | 4.1000 |
| Open | 4.1100 |
| Bid | 0.0000 x 1300 |
| Ask | 0.0000 x 1100 |
| Day's range | 4.1100 - 4.2800 |
| 52-week range | 1.7950 - 6.5200 |
| Volume | |
| Avg. volume | 1,464,941 |
| Market cap | 557.863M |
| Beta (5Y monthly) | 1.43 |
| PE ratio (TTM) | 38.64 |
| EPS (TTM) | 0.1100 |
| Earnings date | 07 Aug 2023 - 11 Aug 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 10.00 |
Motley FoolWhy Shares of Organogenesis Climbed Wednesday
Shares of Organogenesis (NASDAQ: ORGO) were up 15.4% Wednesday afternoon after being up as much as 21.2% Wednesday morning. The healthcare company sells advanced wound care products for surgical and sports medicine applications. Integra LifeSciences said on Tuesday that it was doing a voluntary recall of products, which could be worth as much as $60 million if the recall lasts all of 2023.
Motley FoolWhy Shares of Organogenesis Holdings Jumped Thursday
Shares of Organogenesis Holdings (NASDAQ: ORGO) were up more than 30% Thursday afternoon after the healthcare company released first-quarter earnings after market close on Wednesday. Organogenesis makes products for the advanced wound care, surgical, and sports medicine markets, using regenerative tissue-based technologies that heal chronic and acute wounds. In the company's earnings call, Organogenesis president and CEO Gary Gillheeney said the biggest drivers of sales in the quarter came from its PuraPly antimicrobial wound mix and non-PuraPly products, such as NuShield, a dehydrated placental allograft wound covering.
Motley FoolOrganogenesis (ORGO) Q1 2023 Earnings Call Transcript
Welcome, ladies and gentlemen to the first quarter of fiscal year 2023 earnings conference call for the Organogenesis Holdings Inc. At this time, all participants have been placed in a listen-only mode. Before we begin, I would like to remind everyone that our remarks today may contain forward-looking statements that are based on the current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including the risks and uncertainties described in the company's filings with the Securities and Exchange Commission, including Item 1A Risk Factors of the company's most recent annual report and its subsequently filed quarterly reports. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made.
Motley FoolWhy Shares of Unisys, Organogenesis, and Motorcar Parts of America Fell Today
Shares of Unisys (NYSE: UIS), Organogenesis Holdings (NASDAQ: ORGO), and Motorcar Parts of America (NASDAQ: MPAA) fell today as all three stocks were removed from the S&P SmallCap 600 index as part of its quarterly rebalancing. Unisys closed the day down 14.1%, Organogenesis lost 18.5%, and Motorcar Parts of America gave up 12.2%. There are several reasons stocks fall when they're removed from a major index like the S&P SmallCap 600.
- Motley Fool
Organogenesis (ORGO) Q4 2022 Earnings Call Transcript
Welcome, ladies and gentlemen, to the fourth quarter and fiscal year 2022 earnings conference call for Organogenesis Holdings Inc. At this time, all participants have been placed in listen-only mode. Before we begin, I would like to remind everyone that our remarks today may contain forward-looking statements that are based on the current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including the risks and uncertainties described in the company's filings with the Securities and Exchange Commission, including Item 1A Risk Factors of the company's most recent annual report and its subsequently filed quarterly reports. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made.
Motley FoolOrganogenesis Holdings Inc. (ORGO) Q3 2022 Earnings Call Transcript
Good afternoon, ladies and gentlemen, and welcome to the third quarter 2022 earnings conference call for Organogenesis Holdings Inc. [Operator instructions] Please note that this conference call is being recorded and that the recording will be available on the company's website for replay shortly. Before we begin, I would like to remind everyone that our remarks today may contain forward-looking statements that are based on the current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated Including the risks and uncertainties described in the company's filings with the Securities and Exchange Commission, including Item 1A risk factors of the company's most recent annual report and its subsequently files quarterly report.
- Motley Fool
Why Organogenesis Stock Is Tumbling Today
Shares of Organogenesis Holdings (NASDAQ: ORGO) fell by 19.6% as of 2:45 p.m. ET on Wednesday after the wound care company reported worse-than-anticipated Q2 earnings and also slashed its guidance for the rest of 2022. Its net revenue for the quarter was $121.4 million, a decline of 1% year over year, and its net income collapsed by 58% year over year to reach $8.7 million. For its fiscal 2022 earnings guidance, management now expects net revenue of between $465 million and $490 million, whereas in its initial guidance, it expected between $485 million and $515 million.
Motley FoolOrganogenesis Holdings Inc. (ORGO) Q2 2022 Earnings Call Transcript
Good afternoon, ladies and gentlemen, and welcome to the second quarter 2022 earnings conference call for Organogenesis Holdings Inc. [Operator instructions] Please note that this conference call is being recorded and that the recording will be available on the company's website for replay shortly. Let me start with a brief agenda of what we'll be covering during our prepared remarks.
ZacksOrganogenesis (ORGO) Tops Q2 Earnings and Revenue Estimates
Organogenesis (ORGO) delivered earnings and revenue surprises of 12.50% and 0.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?